MBRX Stock — Moleculin Biotech Inc.: Cash, EV, Pipeline

Share price

$0.77

Market cap

$15.1M

Cash

$15.8M

Enterprise value

-$0.7M

Balance sheet

Cash	$15.8M
Debt	$0.0M
Net cash	$15.8M
Enterprise value	-$0.7M
Basic shares	7.1M shares
Fully diluted shares	22.1M shares
Fully diluted market cap	$17.0M
Cash per share	$2.22

Cash figures as of 2026-08-21. Database snapshot: 2026-09-21.

Price history

Loading MBRX daily closes…

Loading price history…

Pipeline assets

Annamycin

Phase 2/3 · Active Modality: small molecule (anthracycline)

Aliases L-Annamycin, naxtarubicin

Target topoisomerase II

Partnerships University of Texas MD Anderson Cancer Center (license; sponsored research)

Indications

Relapsed/refractory acute myeloid leukemia (R/R AML) (Phase 2/3)
Soft tissue sarcoma lung metastases (Phase 2)
Pancreatic cancer (3rd line) (Stage not disclosed)

Catalysts

— None

Status note Pivotal Phase 2B/3 MIRACLE trial (MB-108) in R/R AML. Phase 1B/2 STS lung mets trials completed. Physician-sponsored Phase 1B/2 in 3rd-line pancreatic cancer planned for 2026. FDA Fast Track and Orphan Drug designated for AML and soft tissue sarcoma.

WP1066

Phase 2 · Active Modality: small molecule

Target p-STAT3

Partnerships Northwestern University (externally funded physician-sponsored trial)

Indications

Glioblastoma (with radiation) (Phase 2)

Status note Externally funded Phase 1B/2 trial of oral formulation in combination with radiation in glioblastoma actively recruiting in adults; pediatric trial in planning. Prior Emory physician-sponsored Phase 1 in pediatric brain tumors concluded Feb 2023.

WP1122

Stage not disclosed · Active Modality: small molecule

Target glycolysis

Partnerships University of Texas MD Anderson Cancer Center (license)

Indications

not disclosed (Stage not disclosed)

Status note Recommended Phase 2 dose established to potentially enable future externally funded oncology and virology trials; no active trial disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Annamycin
Lead indication	Acute Myeloid Leukaemia (AML)
Lead phase	Phase 3
Active trials	1
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06788756	Phase 3	Recruiting	Sponsor	MBRX	—	Acute Myeloid Leukaemia (AML)	—
NCT05879250	Phase 2	Recruiting	Collaborator	Northwestern University	—	Glioblastoma, IDH-Wildtype; MGMT-Unmethylated Glioblastoma	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Moleculin Biotech, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

MBRX — Moleculin Biotech Inc.

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials